FDA approves Siliq (brodalumab) for psoriasis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Siliq (brodalumab), as an injection for the treatment of adults with moderate-to-severe plaque psoriasis. Siliq is intended for patients receiving systemic therapy or phototherapy and have failed to respond other systemic therapies.

Psoriasis is an autoimmune disorder which more commonly occurs in patients with a family history of the disease and most often in people 15 to 35 years of age. Psoriasis cause patches of red skin and flakes. Plaque psoriasis is most common form of psoriasis causing thick, red flaky skin, silver-white scales.

Brodalumab inhibits the inflammatory response responsible for the development of plaque psoriasis by binding to a protein which cause inflammation.

The safety and efficacy of Siliq was established in 3 randomized, placebo-controlled clinical trials of 4,373 adult participants with moderate-to-severe plaque psoriasis who received systemic therapy or phototherapy. Patients treated with Siliq had clear or almost clear skin compared to placebo as evaluated by scoring of the e...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

Recall of Venture catheters by Vascular Solutions- Catheter tip may split or separate during use

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • no comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Radicava (edaravone) for amyotrophic lateral sclerosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Use of Medtronic’s NavLock Tracker with non-Medtronic instruments can cause spinal injury or death

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rydapt (midostaurin) for acute myeloid leukemia

Read more
  • FDA Drug Updates
  • no comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • FDA Drug Updates
  • no comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators by Zimmer Biomet

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Mibela 24 Fe chewable tablet by Lupin Pharmaceuticals Inc- Packaging error affecting dosing regimen

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of physician sample of Brilinta (ticagrelor) 90mg by AstraZeneca- Presence of another medicine Zurampic

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of HeartMate II LVAS Pocket System Controller by Abbott-Thoratec- Controller malfunction after exchange

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of V60 Non-invasive ventilator by Respironics- Unexpected stop in ventilation therapy

Read more
  • MedWatch Drug Updates
  • 1 comment

Gadolinium-based contrast agent for MRI- No adverse effects reported with gadolinium retention in the brain

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Tri-Ton by Dynamic Technical Formulations LLC- Presence of unapproved drug andarine and ostarine

Read more
  • FDA Drug Updates
  • no comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Dupixent (dupilumab) for atopic dermatitis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Zejula (niraparib) for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more
  • MedWatch Drug Updates
  • no comment

Safety alert against LeadCare Testing Systems by Magellan Diagnostics due to inaccurate test results

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Coronary Catheters by Abbott due to difficulty in removing the protective balloon sheath

Read more